Literature DB >> 21242888

NF-κB/Rel: agonist and antagonist roles in HIV-1 latency.

Jonathan K L Chan1, Warner C Greene.   

Abstract

PURPOSE OF REVIEW: To discuss recent advances in our understanding of the diverse roles of NF-κB/Rel family members in HIV-1 latency. RECENT
FINDINGS: Various NF-κB/Rel family members can reinforce maintenance of HIV-1 latency. For example, p50 recruits histone deacetylase 1 to the HIV-1 long terminal repeat promoting chromatin condensation and reduced RNA Pol II recruitment. Low-level NF-κB activation during homeostatic proliferation of memory CD4 T cells induced by IL-7 and TCR signaling or OX40 action promotes expression of antiapoptotic gene targets such as BCL2 and BCLXL. Additionally, the IκB kinase phosphorylates FOXO3a transcription factor, blocking its induction of proapoptotic genes. These combined effects promote memory CD4 T-cell survival, thus maintaining the latent reservoir. Conversely, when the nontumorigenic phorbol ester prostratin is combined with histone deacetylase inhibitors, potent synergistic activation of latent HIV-1 occurs involving nuclear expression of NF-κB.
SUMMARY: These recent findings highlight both the antagonistic and agonistic effects of the NF-κB signaling pathway on HIV-1 latency. Synergistic inducers might be useful for flushing of latent virus from reservoirs in infected patients. The ultimate, albeit lofty, goal is to achieve full viral eradication. However, a more reasonable goal might be a functional cure where patients experience a drug-free remission.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21242888      PMCID: PMC3493179          DOI: 10.1097/COH.0b013e32834124fd

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  47 in total

1.  NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II.

Authors:  M Barboric; R M Nissen; S Kanazawa; N Jabrane-Ferrat; B M Peterlin
Journal:  Mol Cell       Date:  2001-08       Impact factor: 17.970

2.  Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).

Authors:  Hans-Jürgen Stellbrink; Jan van Lunzen; Michael Westby; Eithne O'Sullivan; Claus Schneider; Axel Adam; Lutwin Weitner; Birger Kuhlmann; Christian Hoffmann; Stefan Fenske; Philipp S Aries; Olaf Degen; Christian Eggers; Heiko Petersen; Friedrich Haag; Heinz A Horst; Klaus Dalhoff; Christiane Möcklinghoff; Nick Cammack; Klara Tenner-Racz; Paul Racz
Journal:  AIDS       Date:  2002-07-26       Impact factor: 4.177

3.  Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes.

Authors:  Yefei Han; Kara Lassen; Daphne Monie; Ahmad R Sedaghat; Shino Shimoji; Xiao Liu; Theodore C Pierson; Joseph B Margolick; Robert F Siliciano; Janet D Siliciano
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

4.  Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy.

Authors:  J M Prins; S Jurriaans; R M van Praag; H Blaak; R van Rij; P T Schellekens; I J ten Berge; S L Yong; C H Fox; M T Roos; F de Wolf; J Goudsmit; H Schuitemaker; J M Lange
Journal:  AIDS       Date:  1999-12-03       Impact factor: 4.177

5.  HIV reproducibly establishes a latent infection after acute infection of T cells in vitro.

Authors:  Albert Jordan; Dwayne Bisgrove; Eric Verdin
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

6.  Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB.

Authors:  Lin-feng Chen; Yajun Mu; Warner C Greene
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

7.  Duration of nuclear NF-kappaB action regulated by reversible acetylation.

Authors:  W Fischle; E Verdin; W C Greene
Journal:  Science       Date:  2001-08-31       Impact factor: 47.728

8.  Protein kinase Calpha (PKCalpha) acts upstream of PKCtheta to activate IkappaB kinase and NF-kappaB in T lymphocytes.

Authors:  Sergey A Trushin; Kevin N Pennington; Eva M Carmona; Susana Asin; Doris N Savoy; Daniel D Billadeau; Carlos V Paya
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

9.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

10.  Structure of NFAT1 bound as a dimer to the HIV-1 LTR kappa B element.

Authors:  Michael J Giffin; James C Stroud; Darren L Bates; Konstanze D von Koenig; John Hardin; Lin Chen
Journal:  Nat Struct Biol       Date:  2003-08-31
View more
  38 in total

1.  The viral protein Tat can inhibit the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Björn D Kuhl; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

2.  Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-κB-dependent manner.

Authors:  Lara Manganaro; Lars Pache; Tobias Herrmann; John Marlett; Young Hwang; Jeffrey Murry; Lisa Miorin; Adrian T Ting; Renate König; Adolfo García-Sastre; Frederic D Bushman; Sumit K Chanda; John A T Young; Ana Fernandez-Sesma; Viviana Simon
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

3.  Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV.

Authors:  Geetha H Mylvaganam; Lynette S Chea; Gregory K Tharp; Sakeenah Hicks; Vijayakumar Velu; Smita S Iyer; Claire Deleage; Jacob D Estes; Steven E Bosinger; Gordon J Freeman; Rafi Ahmed; Rama R Amara
Journal:  JCI Insight       Date:  2018-09-20

Review 4.  Developing strategies for HIV-1 eradication.

Authors:  Christine M Durand; Joel N Blankson; Robert F Siliciano
Journal:  Trends Immunol       Date:  2012-08-03       Impact factor: 16.687

5.  Heat Shock Protein 90 Facilitates Latent HIV Reactivation through Maintaining the Function of Positive Transcriptional Elongation Factor b (p-TEFb) under Proteasome Inhibition.

Authors:  Xiao-Yan Pan; Wei Zhao; Chun-Yan Wang; Jian Lin; Xiao-Yun Zeng; Ru-Xia Ren; Keng Wang; Tian-Rong Xun; Yechiel Shai; Shu-Wen Liu
Journal:  J Biol Chem       Date:  2016-10-31       Impact factor: 5.157

6.  Chromatin accessibility at the HIV LTR promoter sets a threshold for NF-κB mediated viral gene expression.

Authors:  Kathryn Miller-Jensen; Siddharth S Dey; Nhung Pham; Jonathan E Foley; Adam P Arkin; David V Schaffer
Journal:  Integr Biol (Camb)       Date:  2012-05-03       Impact factor: 2.192

Review 7.  Progress and challenges in the use of latent HIV-1 reactivating agents.

Authors:  Hong-tao Shang; Ji-wei Ding; Shu-ying Yu; Tao Wu; Qiu-li Zhang; Fu-jun Liang
Journal:  Acta Pharmacol Sin       Date:  2015-06-01       Impact factor: 6.150

8.  NF-κB-Interacting Long Noncoding RNA Regulates HIV-1 Replication and Latency by Repressing NF-κB Signaling.

Authors:  Hong Wang; Yue Liu; Chen Huan; Jing Yang; Zhaolong Li; Baisong Zheng; Yingchao Wang; Wenyan Zhang
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

9.  Fold-Change Detection of NF-κB at Target Genes with Different Transcript Outputs.

Authors:  Victor C Wong; Shibin Mathew; Ramesh Ramji; Suzanne Gaudet; Kathryn Miller-Jensen
Journal:  Biophys J       Date:  2019-01-12       Impact factor: 4.033

10.  Dilazep synergistically reactivates latent HIV-1 in latently infected cells.

Authors:  Hanxian Zeng; Sijie Liu; Pengfei Wang; Xiying Qu; Haiyan Ji; Xiaohui Wang; Xiaoli Zhu; Zhishuo Song; Xinyi Yang; Zhongjun Ma; Huanzhang Zhu
Journal:  Mol Biol Rep       Date:  2014-08-05       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.